BioMarin Pharma (BMRN) Tops Q2 EPS by 8c, Affirms FY Revenue Guidance, Lowers R&D Expense Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $126 at SunTrust Robinson Humphrey
August 3, 2018 2:32 PM EDTSunTrust Robinson Humphrey raised its price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $126.00 (from $121.00) while maintaining a Buy rating.
Analyst Edward Nash commented, "BioMarin reported a strong 2nd quarter. All but Kuvan's net product sales beat Street consensus. Prior guidance... More
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $109 at Stifel
August 3, 2018 9:36 AM EDTStifel raised its price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $109.00 (from $102.00) while maintaining a Buy rating.
... MoreBioMarin Pharmaceutical Inc. (BMRN) PT Raised to $98 at Barclays
August 3, 2018 5:06 AM EDTBarclays raised its price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $98.00 (from $95.00) while maintaining a Equalweight rating.
... More